Medtronic plc MDT
Verdict: Strong sell. Fair value $72.66 against a price of $97.36 on 6 Jan 2026, 25% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Net Income has shown significant volatility ($5.04B in 2022, dropping to $3.68B in 2024, then....
Main risks
- Negative Return on Incremental Invested Capital (ROIIC): Proxy calculation suggests recent investments have been value-destructive, with incremental capital generating lower EBIT. This is a severe red flag regarding capital allocation efficiency.
- Sluggish Growth: Revenue CAGR of ~2-4% is low for a company of this scale and indicates market saturation or competitive pressures, barely keeping pace with inflation.
- Sub-par Profitability and Returns: Key metrics like ROE (9.7%) and proxied ROIC (4.2%) are weak for the industry, suggesting operational inefficiencies or a lack of competitive advantage to command higher margins and returns.
- Intense competitive environment
- Valuation prices in optimistic scenario (limited margin for error)